Verona Pharma plc is a biotechnology business based in the UK. Verona Pharma shares (VRP.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Its last market close was 25.85p – an increase of 0.19% over the previous week. Verona Pharma employs 33 staff and has a market cap (total outstanding shares value) of £228 million.
Since the stock market crash in March caused by coronavirus, Verona Pharma's share price has had significant negative movement.
Its last market close was 25.85p, which is 60.20% down on its pre-crash value of 64.95p and 10.64% down on the lowest point reached during the March crash when the shares fell as low as 28.6p.
If you had bought £1,000 worth of Verona Pharma shares at the start of February 2020, those shares would have been worth £670.10 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £532.99.
|Latest market close||25.85p|
|52-week range||13.33p - 26.46p|
|50-day moving average||55p|
|200-day moving average||62.902p|
|Wall St. target price||247.67p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-18.7p|
|Gross profit TTM||£0|
|Return on assets TTM||-45.08%|
|Return on equity TTM||0%|
|Market capitalisation||£228 million|
TTM: trailing 12 months
We're not expecting Verona Pharma to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Verona Pharma's shares were split on a 1:50 basis on 13 February 2017. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Verona Pharma shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Verona Pharma shares which in turn could have impacted Verona Pharma's share price.
Over the last 12 months, Verona Pharma's shares have ranged in value from as little as 13.33p up to 26.46p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Verona Pharma's is -0.4932. This would suggest that Verona Pharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Verona Pharma has bucked the trend.
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.